Novalis Biotechnology Incubation

Novalis Biotechnology Incubation is a venture capital firm based in Ghent, Belgium, founded in 2018. The company is dedicated to seeding and supporting early-stage start-ups in the biotechnology and life sciences sectors. By providing essential funding and leveraging its extensive professional and academic networks, Novalis aids these start-ups in developing their business strategies and navigating the complexities of the industry. The firm's focus is on creating value for all stakeholders involved in the growth and success of the companies it incubates, fostering innovation and advancement within the healthcare landscape.

Wim van Criekinge

Co-Founder and Managing Director

6 past transactions

Rarity Bioscience

Seed Round in 2023
Rarity Bioscience provides multiplex assays for detecting nucleic acid sequences in biological samples like liquid biopsies.

Alithea Genomics

Seed Round in 2022
Alithea Genomics backgrounds in bioengineering, molecular biology, genomics and lab operations reflect their complementary expertise.

Modality.AI, Inc.

Seed Round in 2021
Modality.ai is an AI-powered platform that detects health conditions using conversational AI. Through dialogue and video, Modality.AI interacts conversationally with the patient to provide health assessment anywhere, anytime. Its system analyzes multimodal data which allows continuous screening and assessing of patients’ health.

RheaVita

Series A in 2021
RheaVita is a pharmaceutical company developing continuous freeze-drying technology for biopharmaceutical products. The company technology integrates all freeze-drying process step unit operations in a continuous production line with the constant infeed of products and the concomitant outfeed of the dried product. Its manufacturing approach avoids scale-up issues, reduces cycle times, allows fast product development, reduces time-to-market, lowers production costs, makes use of smaller manufacturing installations, requires less clean room space, provides improved quality assurance (100% inspection with inherent potential for real-time-release) and leads to improved and uniform product quality and process uniformity.

GRAPHEAL

Seed Round in 2021
Grapheal is a Medtech startup, which produces embedded and wearable biosensors, digital by design, minimalistic in components, with capabilities to dose biomarkers and detect pathogens anywhere with a simple smartphone. Wireless electronic biosensors produced by Grapheal are based on graphene transistors which make field diagnostics and remote patient monitoring affordable & accurate.

Enzyre

Debt Financing in 2020
Enzyre is a developer of diagnostic technology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.